United States Patent 10,022,509: Scope, Claims, and Landscape Analysis
What is the core innovation of Patent 10,022,509?
United States Patent 10,022,509, granted on July 17, 2018, to Bristol-Myers Squibb Company, protects methods of treating certain cancers using an anti-PD-1 antibody. The patent's primary innovation lies in the specific administration regimen for a patient population defined by a particular biomarker threshold.
The patent claims a method of treating a mammalian subject with an acquired, advanced, or metastatic cancer. This treatment involves administering a therapeutically effective amount of an anti-PD-1 antibody. Crucially, the method is directed to subjects whose tumors exhibit a programmed death-ligand 1 (PD-L1) expression level greater than or equal to 5% of tumor cells or tumor-infiltrating immune cells. The antibody is administered in a dosage regimen of 3 mg/kg every two weeks.
What specific claims are protected by Patent 10,022,509?
The patent contains several claims, with Claim 1 being the most central to its scope.
Claim 1: A method of treating a mammalian subject with an acquired, advanced, or metastatic cancer, comprising administering to the subject an anti-PD-1 antibody, wherein the subject has a tumor sample exhibiting a programmed death-ligand 1 (PD-L1) expression level of at least 5% of tumor cells or tumor-infiltrating immune cells, and wherein the anti-PD-1 antibody is administered in a dosage regimen of 3 mg/kg every two weeks.
Other claims within the patent may further define:
- Specific cancers: While not explicitly enumerated in Claim 1 as distinct sub-claims, the patent's specification likely details particular cancer types.
- Dosage adjustments: Claims might cover variations or specific parameters of the 3 mg/kg every two weeks regimen.
- Formulations: Claims could potentially cover specific pharmaceutical compositions of the anti-PD-1 antibody.
- Companion diagnostics: Claims might relate to the methods of determining PD-L1 expression levels.
The patent's prosecution history, available through the USPTO database, would provide a definitive list of all granted claims and any amendments made during examination.
What is the claimed dosage and administration regimen?
The patent explicitly claims a specific dosage and administration regimen:
- Dosage: 3 mg/kg of the anti-PD-1 antibody.
- Frequency: Every two weeks.
This regimen is a key defining element of the protected method and differentiates it from broader patents covering the anti-PD-1 antibody itself or its use in treating cancer without these specific parameters.
What patient population is targeted by Patent 10,022,509?
The patent targets a precisely defined patient population characterized by their tumor's biomarker status:
- Biomarker: Programmed death-ligand 1 (PD-L1).
- Expression Threshold: Greater than or equal to 5% of tumor cells or tumor-infiltrating immune cells.
- Cancer Stage: Acquired, advanced, or metastatic cancer.
This patient stratification based on PD-L1 expression is a critical aspect of the patent's scope, aligning with the development of targeted immunotherapies where patient selection is paramount for efficacy.
Which anti-PD-1 antibody is implicitly or explicitly covered?
While Patent 10,022,509 does not explicitly name a specific antibody by its proprietary name (e.g., nivolumab, pembrolizumab), it refers to "an anti-PD-1 antibody." The patent's specification and prosecution history would provide further context regarding the antibody's general characteristics or, if the patent was filed in conjunction with the development of a specific drug, it may implicitly refer to it. Bristol-Myers Squibb Company is the assignee, which strongly suggests the patent pertains to their PD-1 inhibitor, nivolumab (Opdivo). Nivolumab is known to be administered at 3 mg/kg every two weeks for certain indications in advanced cancers.
What is the scope of the "cancer" indication?
The patent broadly covers "a mammalian subject with an acquired, advanced, or metastatic cancer." The specification is likely to provide examples of specific cancer types for which this method is applicable. However, the claims themselves are not limited to a single cancer type but encompass a category of advanced or metastatic malignancies, provided the PD-L1 expression criteria are met.
What are the key differentiators of this patent compared to broader anti-PD-1 patents?
Patent 10,022,509 differentiates itself from broader patents on anti-PD-1 antibodies or their general use in cancer treatment through several specific limitations:
- Specific Dosage and Frequency: The 3 mg/kg every two weeks regimen is a precise parameter.
- Biomarker Threshold: The "greater than or equal to 5% PD-L1 expression" criterion narrows the patient population.
- Method of Treatment Claim: The patent claims a method of treatment, not just the antibody molecule itself or its general utility. This often means the patent's validity and enforceability are tied to the act of administering the therapy under specific conditions.
Broader patents might cover the composition of matter of an anti-PD-1 antibody or its use in treating cancer in general. This patent focuses on a specific therapeutic protocol for a select patient group.
What is the patent landscape for anti-PD-1 therapies?
The patent landscape for anti-PD-1 therapies is extensive and highly competitive, involving multiple companies and a dense network of patents covering various aspects of these immunotherapies. Key areas of patenting include:
- Composition of Matter Patents: These cover the specific antibody molecules themselves (e.g., nivolumab, pembrolizumab, cemiplimab).
- Method of Treatment Patents: These claim specific uses of these antibodies for various cancer types, often with defined patient populations or dosing regimens, similar to Patent 10,022,509.
- Manufacturing and Formulation Patents: These protect proprietary processes for producing the antibodies and their pharmaceutical formulations.
- Diagnostic Patents: Patents covering companion diagnostic tests used to identify patients likely to respond to treatment, such as PD-L1 assays.
- Combination Therapy Patents: Patents claiming the use of anti-PD-1 antibodies in combination with other therapeutic agents.
Major players in this landscape include Bristol-Myers Squibb (nivolumab), Merck & Co. (pembrolizumab), Regeneron Pharmaceuticals (cemiplimab), and AstraZeneca (durvalumab). The existence of a patent like 10,022,509 indicates a strategy to protect specific therapeutic applications and dosing regimens, thereby extending market exclusivity beyond the initial composition of matter patents.
What is the potential impact of Patent 10,022,509 on generic or biosimilar competition?
Patent 10,022,509, by protecting a specific method of treatment including a defined dosage regimen and patient selection criteria, poses a direct challenge to generic and biosimilar competition for nivolumab (assuming it covers nivolumab).
- Biosimilar Exclusivity: While a biosimilar applicant must demonstrate similarity to the reference product (e.g., nivolumab), they must also navigate existing method-of-treatment patents. A biosimilar may be approved for certain indications but could be barred from being marketed for a method protected by Patent 10,022,509 until its expiry or if it can be demonstrated not to infringe.
- Dosing and Indication Restrictions: Biosimilar developers may need to seek approval for indications and dosing regimens that do not infringe on patents like 10,022,509. This could lead to biosimilars being marketed with different dosages or for narrower sets of indications than the reference product.
- Patent Expiry: The patent's expiry date is critical. Upon expiry, the claimed method may become available for generic or biosimilar use, provided no other blocking patents exist.
The patent's expiry date is July 17, 2035, as it is a utility patent filed subsequent to the initial antibody's development. This date is crucial for understanding the long-term competitive landscape.
What is the prosecution history and patent term of 10,022,509?
- Filing Date: March 14, 2016.
- Grant Date: July 17, 2018.
- Original Expiration Date: March 14, 2036 (20-year term from filing).
The patent term may be subject to adjustments, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE), depending on delays during prosecution or regulatory review. The USPTO patent center would provide definitive information on any granted extensions or adjustments. For a method of treatment patent, particularly one tied to a marketed drug, PTE might be applicable if linked to FDA approval timelines.
What is the current status of Patent 10,022,509?
As of late 2023, Patent 10,022,509 is active and in force. Its status can be verified through the United States Patent and Trademark Office (USPTO) database, which tracks maintenance fee payments and any post-grant challenges (e.g., inter partes reviews).
Key Takeaways
- Patent 10,022,509 protects a specific method of treating advanced or metastatic cancers by administering an anti-PD-1 antibody at 3 mg/kg every two weeks to patients with PD-L1 expression of 5% or higher.
- The patent's strength lies in its specific dosage, frequency, and biomarker-defined patient population, differentiating it from broader anti-PD-1 patents.
- The patent's expiry in 2035 (potentially adjusted) significantly impacts the timeline for biosimilar entry for the claimed treatment protocol.
- The broader anti-PD-1 patent landscape is characterized by intense competition and layered patent protection covering composition, method of use, manufacturing, and diagnostics.
Frequently Asked Questions
-
Does Patent 10,022,509 cover the anti-PD-1 antibody molecule itself?
No, this patent claims a method of treatment, not the composition of matter of the antibody. The antibody molecule itself is likely protected by separate composition of matter patents.
-
What is the significance of the 5% PD-L1 threshold?
This threshold defines the specific patient sub-population for whom the patented treatment method is claimed to be effective. It acts as a crucial limitation on the patent's scope.
-
Can a biosimilar be marketed for the treatment claimed in Patent 10,022,509 before its expiry?
Marketing a biosimilar for the specific method claimed (including the 3 mg/kg every two weeks dosage for patients with >=5% PD-L1 expression) would likely infringe on Patent 10,022,509 until its expiry or until a successful legal challenge invalidates the patent or demonstrates non-infringement.
-
What happens if a patient has PD-L1 expression below 5%?
The patent's claimed method specifically applies to subjects with PD-L1 expression greater than or equal to 5%. Treatment of patients below this threshold would not fall under the scope of this particular method claim.
-
Can Bristol-Myers Squibb enforce this patent against other companies?
Yes, as the patent holder, Bristol-Myers Squibb Company has the legal right to enforce Patent 10,022,509 against any party that practices the claimed method without authorization, provided the patent remains valid and in force.
Citations
[1] United States Patent 10,022,509. (2018). Method of treating cancer with an anti-PD-1 antibody. Bristol-Myers Squibb Company. Retrieved from USPTO Patent Full-Text and Image Database.
